BIOMARKER COMPOSITION FOR DETERMINING CANCER DRUG RESPONSIVENESS, METHOD FOR DETERMINING CANCER DRUG RESPONSIVENESS USING BIOMARKER COMPOSITION, AND DIAGNOSTIC CHIP FOR DETECTING BIOMARKER COMPOSITION FOR DETERMINING CANCER DRUG RESPONSIVENESS

• Main Authors: JUNG, Jongsun, LEE, Sunho, HONG, Jonghui
• Format: Patent
• Language: English; French; Korean
• Published: 06.08.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The present invention relates to a biomarker composition for determining the responsiveness of a discovered cancer drug by using genetic biomarker labeling scan (GBLscan), which is a drug indication and responsiveness prediction system and method, as a new learning model capable of reliably predicting the responsiveness of a drug by performing coupling analysis on a molecular profile of the drug after transforming specific genetic variation fingerprints related to diseases including cancer into a haplotype having functional information, a method for determining cancer drug responsiveness using the biomarker composition, and a diagnostic chip for detecting a biomarker composition for determining cancer drug responsiveness. La présente invention concerne une composition de biomarqueur de détermination de la réactivité d'un médicament contre un cancer découvert à l'aide d'un balayage de marquage de biomarqueur génétique (GBLscan), qui est un système et une méthode d'indication de médicament et de prédiction de réactivité de médicament, en tant que nouveau modèle d'apprentissage pouvant prédire de manière fiable la réactivité d'un médicament par application d'une analyse de couplage à un profil moléculaire du médicament après transformation d'empreintes de variation génétique spécifiques associées à des maladies comprenant le cancer dans un haplotype comportant des informations fonctionnelles, une méthode de détermination de réactivité d'un médicament contre le cancer à l'aide de la composition de biomarqueur, et une puce de diagnostic de détection d'une composition de biomarqueur de détermination de réactivité d'un médicament contre le cancer. 본 발명은 암을 포함하는 질병 관련 특이 유전자 변이 지문 (Genetic Variation Fingerprints)을 기능정보를 가진 하플로타입으로 변형 후 약물의 분자 프로파일의 결합분석에 의해 약물의 반응성을 신뢰성 있게 예측할 수 있는 새로운 학습모델인 약물 적응증 및 반응 예측 시스템 및 방법인 GBLscan(Genetic biomarker Labeling Scan)을 이용하여, 발굴된 암 약물 반응성 판단을 위한 바이오 마커 조성물, 바이오 마커 조성물을 이용한 암 약물 반응성 판단 방법 및 암 약물 반응성 판단을 위한 바이오 마커 조성물 검출용 진단칩에 관한 것이다.